KR910004573B1 - 작용 지속형 세파클로르 제제의 제조 방법 - Google Patents

작용 지속형 세파클로르 제제의 제조 방법 Download PDF

Info

Publication number
KR910004573B1
KR910004573B1 KR1019840003359A KR840003359A KR910004573B1 KR 910004573 B1 KR910004573 B1 KR 910004573B1 KR 1019840003359 A KR1019840003359 A KR 1019840003359A KR 840003359 A KR840003359 A KR 840003359A KR 910004573 B1 KR910004573 B1 KR 910004573B1
Authority
KR
South Korea
Prior art keywords
ccl
soluble
sephachlor
preparation
fat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR1019840003359A
Other languages
English (en)
Korean (ko)
Other versions
KR850000242A (ko
Inventor
데루오 사까모도
사다오 가와이
긴자부로 노다
도요히고 다께다
히로시 가또
Original Assignee
시오노기세이야꾸 가부시끼가이샤
요시또시 가즈오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시오노기세이야꾸 가부시끼가이샤, 요시또시 가즈오 filed Critical 시오노기세이야꾸 가부시끼가이샤
Publication of KR850000242A publication Critical patent/KR850000242A/ko
Application granted granted Critical
Publication of KR910004573B1 publication Critical patent/KR910004573B1/ko
Expired legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1019840003359A 1983-06-15 1984-06-15 작용 지속형 세파클로르 제제의 제조 방법 Expired KR910004573B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP108289 1983-06-15
JP58108289A JPS601128A (ja) 1983-06-15 1983-06-15 作用持続型セフアクロル製剤

Publications (2)

Publication Number Publication Date
KR850000242A KR850000242A (ko) 1985-02-26
KR910004573B1 true KR910004573B1 (ko) 1991-07-06

Family

ID=14480890

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840003359A Expired KR910004573B1 (ko) 1983-06-15 1984-06-15 작용 지속형 세파클로르 제제의 제조 방법

Country Status (23)

Country Link
US (1) US4713247A (en:Method)
EP (1) EP0129382B1 (en:Method)
JP (1) JPS601128A (en:Method)
KR (1) KR910004573B1 (en:Method)
AT (1) ATE56869T1 (en:Method)
AU (1) AU568654B2 (en:Method)
BG (1) BG60261B1 (en:Method)
CA (1) CA1213218A (en:Method)
DD (1) DD216163A5 (en:Method)
DE (1) DE3483282D1 (en:Method)
DK (2) DK291884A (en:Method)
ES (1) ES533901A0 (en:Method)
FI (1) FI84556C (en:Method)
GB (1) GB2141342B (en:Method)
GR (1) GR81598B (en:Method)
HU (1) HU193434B (en:Method)
IE (1) IE58278B1 (en:Method)
IL (1) IL72083A (en:Method)
NZ (1) NZ208345A (en:Method)
PH (1) PH19902A (en:Method)
PT (1) PT78699B (en:Method)
RO (1) RO88924A (en:Method)
ZA (1) ZA844357B (en:Method)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229132A (en) * 1985-02-22 1993-07-20 Grimberg Georges Serge Non-absorbable gastrointestinal medicament provided for treating the two levels of the digestive tract at the same time
JPS61210025A (ja) * 1985-03-14 1986-09-18 Teisan Seiyaku Kk 安定化された抗生物質複合顆粒製剤
JPS62226926A (ja) * 1986-03-27 1987-10-05 Teisan Seiyaku Kk 持続性複合顆粒剤
AU591248B2 (en) * 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
JPH0714863B2 (ja) * 1986-06-02 1995-02-22 忠生 白石 時差溶解性の入浴剤
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
ZA881301B (en) * 1987-02-27 1989-10-25 Lilly Co Eli Sustained release matrix formulations
BE1002079A4 (fr) * 1988-07-01 1990-06-19 S M B Lab Composition pharmaceutique d'erythromycine a liberation prolongee, sa preparation et son utilisation.
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
AU8219191A (en) * 1990-06-14 1992-01-07 Kalmo Enterprises, Inc. Stable aqueous drug suspensions
GB9318641D0 (en) * 1993-09-08 1993-10-27 Edko Trading Representation Compositions
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
AU5107496A (en) * 1996-03-13 1997-10-01 Labtec Gesellschaft Fur Technologische Forschung Und Entwicklung Mbh Medicament preparation for angiotensin converting enzyme (ace)-inhibitors
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
ZA98728B (en) * 1998-01-29 1998-10-28 Ranbaxy Lab Ltd Modified release matrix formulations of cefactor and cephalexin
KR100296413B1 (ko) * 1998-04-01 2001-11-14 김선진 세파클러함유서방성정제
EP1165054A4 (en) 1999-04-06 2005-02-09 Pharmaquest Ltd PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT DELIVERY OF METHYLPHENIDATE
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
AU4441899A (en) * 1999-05-14 2000-12-05 Eli Lilly And Company Process for preparing pharmaceutical bulk material having uniform dissolution
US6596307B1 (en) 1999-06-15 2003-07-22 Eli Lilly And Company Process for preparing pharmaceutical bulk material having uniform dissolution
AU2001239869B2 (en) * 2000-02-24 2005-12-15 Shionogi, Inc. Antibiotic composition with inhibitor
EP1267765A4 (en) * 2000-02-24 2008-12-24 Middlebrook Pharmaceuticals In ANTIBIOTIC AND MUSHROOM AGENTS
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
EP1257255A4 (en) * 2000-02-24 2008-07-30 Advancis Pharmaceutical Corp THERAPEUTIC PRODUCT, ITS USE AND MANUFACTURE
CA2435305A1 (en) * 2001-01-18 2002-07-25 Natco Pharma Limited Extended release pharmaceutical compositions containing beta-lactam antibiotics
JP2005526059A (ja) * 2002-03-07 2005-09-02 アドバンシス ファーマスーティカル コーポレイション 抗生物質組成物
AU2003219184A1 (en) * 2002-05-09 2003-11-11 Diffucap-Chemobras Quimica E Farmaceutica, Ltda. Novel method of preparing programmed-release compositions containing (s)-1-(n-(1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl)-l-proline and the product thus obtained
US8313775B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
US8313776B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
EP1648418A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
EP1653924A4 (en) * 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2007513869A (ja) * 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
MXPA06002841A (es) * 2003-09-30 2006-06-14 Lupin Ltd Formulacion de liberacion prolongada novedosa de antibioticos de (-lactama.
JP2008535922A (ja) * 2005-04-12 2008-09-04 エラン・ファルマ・インターナショナル・リミテッド 細菌感染を治療するためのセファロスポリンを含む放出制御組成物
US20060287212A1 (en) * 2005-06-02 2006-12-21 Novozymes A/S Blends of inactive particles and active particles
EP1890676A2 (en) 2005-06-02 2008-02-27 Novozymes A/S Blends of inactive particles and active particles
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
MX342330B (es) 2009-05-19 2016-09-26 Celgene Corp Formulaciones de 4-amino-2-(2, 6-dioxopiperidin-3-il) isoindolin-1, 3-diona.
MX2014007312A (es) * 2011-12-19 2014-08-27 Salix Pharmaceuticals Ltd Metodos para el tratamiento y la prevencion de estreñimiento inducido por opioides usando composiciones orales de metilnaltrexona.
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
CN104688701A (zh) * 2015-03-20 2015-06-10 江苏亚邦强生药业有限公司 一种头孢克洛片剂及其制备方法
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN110408670A (zh) * 2019-08-19 2019-11-05 苏州盛达药业有限公司 一种酶催化合成头孢克洛的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US3906086A (en) * 1971-07-19 1975-09-16 Richard G Powers Timed-release aspirin
JPS52139713A (en) * 1976-05-13 1977-11-21 Shionogi & Co Ltd Sustained release cefalexin preparations
US4250166A (en) * 1977-05-27 1981-02-10 Shionogi & Co., Ltd. Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin
GR74995B (en:Method) * 1980-08-27 1984-07-12 Ciba Geigy Ag
JPS5826816A (ja) * 1981-08-11 1983-02-17 Teisan Seiyaku Kk 球形顆粒からなる持続性複合顆粒剤

Also Published As

Publication number Publication date
FI84556B (fi) 1991-09-13
DK291884D0 (da) 1984-06-14
IL72083A (en) 1987-10-30
RO88924A (ro) 1986-04-30
ES8602407A1 (es) 1985-12-01
ATE56869T1 (de) 1990-10-15
PT78699A (pt) 1985-01-01
BG60261B2 (en) 1994-03-31
HU193434B (en) 1987-10-28
PT78699B (en) 1986-07-15
DE3483282D1 (de) 1990-10-31
KR850000242A (ko) 1985-02-26
HUT34692A (en) 1985-04-28
IL72083A0 (en) 1984-10-31
EP0129382A3 (en) 1986-07-09
ES533901A0 (es) 1985-12-01
DD216163A5 (de) 1984-12-05
NZ208345A (en) 1986-12-05
FI842406L (fi) 1984-12-16
CA1213218A (en) 1986-10-28
US4713247A (en) 1987-12-15
IE841444L (en) 1984-12-15
GB2141342B (en) 1986-11-12
DK170922B1 (da) 1996-03-18
DK291884A (da) 1984-12-16
GR81598B (en:Method) 1984-12-11
BG60261B1 (bg) 1994-03-31
AU2941884A (en) 1984-12-20
ZA844357B (en) 1985-06-26
AU568654B2 (en) 1988-01-07
FI842406A0 (fi) 1984-06-13
FI84556C (fi) 1991-12-27
PH19902A (en) 1986-08-13
IE58278B1 (en) 1993-08-25
GB2141342A (en) 1984-12-19
JPS601128A (ja) 1985-01-07
JPS6232166B2 (en:Method) 1987-07-13
GB8414633D0 (en) 1984-07-11
EP0129382A2 (en) 1984-12-27
EP0129382B1 (en) 1990-09-26

Similar Documents

Publication Publication Date Title
KR910004573B1 (ko) 작용 지속형 세파클로르 제제의 제조 방법
EP0142561B1 (en) Long-acting nifedipine preparation
US4263273A (en) Pharmaceutical preparation comprising a cardiac glycoside with a polymer coating
CA2140254C (en) Controlled release morphine preparation
EP0431877B1 (en) Cimetidine pharmaceutical compositions
KR101077061B1 (ko) 경구고형의약
US7135465B2 (en) Sustained release beadlets containing stavudine
NZ201008A (en) Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient
EP0103991A2 (en) Analgesic capsule
HK65393A (en) Slow-release pharmaceutical composition
JPH0248525B2 (en:Method)
JPS6327439A (ja) 持続性薬効製剤
EP1154762B1 (en) Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
JP2939069B2 (ja) ニカルジピン持続性製剤とその製造方法

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

FPAY Annual fee payment

Payment date: 20020514

Year of fee payment: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20030707

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20030707